[ad_1]
Scientists have made a significant discovery in identifying a major cause of inflammatory bowel disease (IBD), which could be addressed with currently available medications.
This development has been heralded as a “massive step forwards” by the research team.
IBD, which includes Crohn’s disease and ulcerative colitis, is increasingly common. In 2022, it was estimated that over half a million people in the UK suffered from IBD, nearly double the previously thought figure of 300,000.
Treatments for IBD vary in effectiveness, and the development of new medications has been hampered by an incomplete understanding of the disease’s causes.
Researchers have now pinpointed a DNA segment that becomes active in certain immune cells, leading to inflammation in the bowels.
Currently, no specific drugs target this segment.
However, drugs used for other conditions that are non-inflammatory have been suggested to be effective. In trials, teams from the Francis Crick Institute, in conjunction with UCL and Imperial College London, demonstrated that these medications reduced inflammation in immune cells and in IBD patient gut samples.
Researchers are looking into how these drugs, which can have side effects on other organs, could be targeted specifically to the immune cells.
Read more:
Louise Thompson discloses stoma bag after extensive health issues
Crohn’s patient: ‘Proof of colostomy bag demanded to verify condition’
IBD sufferers welcome the discovery
Lauren Golightly, who was diagnosed with Crohn’s disease in 2018, shared her story of struggling with symptoms like stomach aches, blood in stools, and irregular bowel movements.
The 27-year-old has faced numerous hospital visits, various treatments, and even surgery for a temporary stoma bag since her diagnosis.
Golightly stated that the unpredictable nature of IBD is one of its most challenging aspects.
She expressed excitement and hope upon learning about the research and its potential impact on those affected by IBD.
‘We’ve found a critical pathway’
James Lee from the Francis Crick Institute and consultant gastroenterologist at the Royal Free Hospital and UCL announced that, starting from a genetic angle, they’ve identified a pathway that plays a considerable role in IBD and other inflammatory conditions.
Lee highlights that they have proven the potential of targeting this pathway therapeutically and are now focused on enhancing the safety and efficacy for future treatments.
Christina Stankey, PhD student and co-first author, emphasized the complexity of IBD and other autoimmune conditions, acknowledging the importance of discovering a central pathway and the possibility of deactivating it with an existing drug.
The research findings have been published in the journal Nature.
[ad_2]
FAQs about the Major IBD Discovery
What is IBD?
Inflammatory bowel disease (IBD) is a term used to describe disorders that involve chronic inflammation of the digestive tract, such as Crohn’s disease and ulcerative colitis.
Have any specific drugs been identified to target the new cause of IBD?
No drugs are currently targeting the DNA segment that causes inflammation in IBD specifically, but existing drugs for non-inflammatory conditions might be repurposed.
What are the next steps for this IBD treatment research?
The research team at the Francis Crick Institute is investigating how to deliver medication directly to immune cells, minimizing side effects on other organs.
How prevalent is IBD in the UK?
As of 2022, it’s estimated that over 500,000 people in the UK suffer from IBD.
